In lung cancer, HDAC inhibitors like vorinostat and romidepsin have shown promise in restoring tumor suppressor activity, sensitizing cancer cells to chemotherapy and immunotherapy, and enhancing anti-tumor immune responses [119]. The gene discussed is HDAC9; the disease is neoplasm.